InsidersTradesSigma
Follow the LAKEFRONT BIOTHERAPEUTICS stock price and the full insider trade history of the company, a publicly traded company based in Belgium. Shares are quoted on BE BE, under the supervision of FSMA. The latest transaction was filed on 12 May 2026 (Purchase). Among the most active insiders: EcoR1 Capital Fund, L.P.. All data is openly available.
56
Insider Decl.
0
Thresholds
€46m
53 ops.
Buy Volume
·
0 ops.
Sell Volume
15Σ signal
Fundamental score
Ranked 1,271 of 26,063 companies
79.2
score / 100
Value67
Quality92
FCF yld-16%
Earn yld18%
EV/EBITDA4.9x
ROE16%
Gross mgn97%
Net mgn29%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 May 2026
Declarations56 total
3,215 shares@ €23.6932.4% of flowShareOtherFSMA:lakefront-biotherapeutics-0
Ideal exit: 5 Feb 2027 (T+270)
6,785 shares@ €23.4567.6% of flowShareOtherFSMA:lakefront-biotherapeutics
Ideal exit: 2 Feb 2027 (T+270)
353,700 shares0Options /warrants for employees or managersOff exchangeFSMA:lakefront-biotherapeutics-15
Ideal exit: 15 Dec 2026 (T+270)
108,800 shares0Options /warrants for employees or managersOff exchangeFSMA:lakefront-biotherapeutics-12
Ideal exit: 15 Dec 2026 (T+270)
108,800 shares0Options /warrants for employees or managersOff exchangeFSMA:lakefront-biotherapeutics-7
Ideal exit: 15 Dec 2026 (T+270)
235,000 shares0Options /warrants for employees or managersOff exchangeFSMA:lakefront-biotherapeutics-4
Ideal exit: 5 Sept 2026 (T+270)
1,559 shares@ €28.84100.0% of flowShareEuronext BrusselsFSMA:lakefront-biotherapeutics-13
Ideal exit: 19 Oct 2026 (T+270)
378 shares@ €28.8433.3% of flowShareEuronext BrusselsFSMA:lakefront-biotherapeutics-5
Ideal exit: 19 Oct 2026 (T+270)
235,000 shares0Options /warrants for employees or managersOff exchangeFSMA:lakefront-biotherapeutics-1
Ideal exit: 5 Sept 2026 (T+270)
378 shares@ €28.8433.3% of flowShareEuronext BrusselsFSMA:lakefront-biotherapeutics-2
Ideal exit: 19 Oct 2026 (T+270)
137 shares@ €28.84100.0% of flowShareEuronext BrusselsFSMA:lakefront-biotherapeutics-10
Ideal exit: 19 Oct 2026 (T+270)
375 shares@ €28.76100.0% of flowShareEuronext BrusselsFSMA:lakefront-biotherapeutics-9
Ideal exit: 19 Oct 2026 (T+270)
378 shares@ €28.8433.3% of flowShareEuronext BrusselsFSMA:lakefront-biotherapeutics-3
Ideal exit: 19 Oct 2026 (T+270)
●
Person closely associated to a member of administrative management or supervisory bodyExecutives
6,336 shares@ €33.267.3% of flowADR / ADSOtherFSMA:galapagos-5
Ideal exit: 24 Apr 2026 (T+270)
●
Person closely associated to a member of administrative management or supervisory bodyExecutives
89,520 shares@ €33.267.0% of flowADR / ADSOtherFSMA:galapagos-28
Ideal exit: 24 Apr 2026 (T+270)
●
Person closely associated to a member of administrative management or supervisory bodyExecutives
8,992 shares@ €32.3610.0% of flowADR / ADSOtherFSMA:galapagos-40
Ideal exit: 21 Apr 2026 (T+270)
●
Person closely associated to a member of administrative management or supervisory bodyExecutives
127,041 shares@ €32.369.7% of flowADR / ADSOtherFSMA:galapagos-30
Ideal exit: 21 Apr 2026 (T+270)
●
Person closely associated to a member of administrative management or supervisory bodyExecutives
16,651 shares@ €30.4317.5% of flowADR / ADSOtherFSMA:galapagos-22
Ideal exit: 20 Apr 2026 (T+270)
●
Person closely associated to a member of administrative management or supervisory bodyExecutives
235,260 shares@ €30.4316.8% of flowADR / ADSOtherFSMA:galapagos-16
Ideal exit: 20 Apr 2026 (T+270)
●
Person closely associated to a member of administrative management or supervisory bodyExecutives
5,129 shares@ €28.305.0% of flowADR / ADSOtherFSMA:galapagos-65
Ideal exit: 15 Mar 2026 (T+270)
25 of 56 declarations
About LAKEFRONT BIOTHERAPEUTICS
Lakefront Biotherapeutics is a company focused on developing innovative biological therapies. It operates in the XBRU market.